Gene enhancer deregulation and epigenetic vulnerability

Rui Lu, G. Wang
{"title":"Gene enhancer deregulation and epigenetic vulnerability","authors":"Rui Lu, G. Wang","doi":"10.18632/oncoscience.334","DOIUrl":null,"url":null,"abstract":"One major goal of cancer research is to identify tumor-specific mechanisms that sustain cell proliferation or survival and to develop the corresponding therapies that target selectively against tumor. Recent sequencing of primary tumor samples supports that aberration of chromatin modification and epigenetic states plays a central role in oncogenesis. For example, mutation of DNA methyltransferase 3A (DNMT3A, Figure 1) occurs in approximately 20-30% of acute myeloid leukemia (AML) and 5-15% of other hematological malignancies and disorders, making DNMT3A one of the most frequently mutated genes in blood cancer [1]; genes encoding chromatin-remodeling protein complexes are found recurrently mutated or deleted in various tumors. Thus, DNMT3A and ATP-dependent chromatin remodelers appear to function as tumor suppressors, most likely, in a context-dependent manner. However, it remains elusive how alteration of chromatin-modifying machineries contributes to tumorigenesis, and mechanism-based therapeutic approaches are to be developed. Chromatin modifications ensure distinctive cellular identities. Past studies have shed light on several principles in chromatin modifications. One important property is reversibility. Epigenomic states are reset in response to developmental or environmental cues such as differentiation. Epigenetic changes are mediated by antagonizing enzymes that ‘write’ or ‘erase’ specific chromatin modification, exemplified by DNA methyltransferase or demethylase, and histone acetyltransferase (HAT) or deacetylase (HDAC). Second, epigenetic states can be relatively stable over cell divisions. Such ‘inheritance’ is partly owing to self-recruitment of modifying enzymes to promote self-propagation. Furthermore, different chromatin modifications that fall into the same gene-active or gene-repressive category often cooperate forming a selfreinforcement network. For example, methylated DNA is ‘read’ by MeCP2, which recruits HDACs to deacetylate histones (Figure 1). Due to the epigenetic crosstalk via antagonizing and reinforcing networks, one would Editorial","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 1","pages":"299 - 301"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncoscience.334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

One major goal of cancer research is to identify tumor-specific mechanisms that sustain cell proliferation or survival and to develop the corresponding therapies that target selectively against tumor. Recent sequencing of primary tumor samples supports that aberration of chromatin modification and epigenetic states plays a central role in oncogenesis. For example, mutation of DNA methyltransferase 3A (DNMT3A, Figure 1) occurs in approximately 20-30% of acute myeloid leukemia (AML) and 5-15% of other hematological malignancies and disorders, making DNMT3A one of the most frequently mutated genes in blood cancer [1]; genes encoding chromatin-remodeling protein complexes are found recurrently mutated or deleted in various tumors. Thus, DNMT3A and ATP-dependent chromatin remodelers appear to function as tumor suppressors, most likely, in a context-dependent manner. However, it remains elusive how alteration of chromatin-modifying machineries contributes to tumorigenesis, and mechanism-based therapeutic approaches are to be developed. Chromatin modifications ensure distinctive cellular identities. Past studies have shed light on several principles in chromatin modifications. One important property is reversibility. Epigenomic states are reset in response to developmental or environmental cues such as differentiation. Epigenetic changes are mediated by antagonizing enzymes that ‘write’ or ‘erase’ specific chromatin modification, exemplified by DNA methyltransferase or demethylase, and histone acetyltransferase (HAT) or deacetylase (HDAC). Second, epigenetic states can be relatively stable over cell divisions. Such ‘inheritance’ is partly owing to self-recruitment of modifying enzymes to promote self-propagation. Furthermore, different chromatin modifications that fall into the same gene-active or gene-repressive category often cooperate forming a selfreinforcement network. For example, methylated DNA is ‘read’ by MeCP2, which recruits HDACs to deacetylate histones (Figure 1). Due to the epigenetic crosstalk via antagonizing and reinforcing networks, one would Editorial
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基因增强子解除管制与表观遗传脆弱性
癌症研究的一个主要目标是确定维持细胞增殖或存活的肿瘤特异性机制,并开发选择性靶向肿瘤的相应治疗方法。最近对原发肿瘤样本的测序支持染色质修饰和表观遗传状态的畸变在肿瘤发生中起核心作用。例如,DNA甲基转移酶3A (DNMT3A,图1)突变发生在大约20-30%的急性髓性白血病(AML)和5-15%的其他血液恶性肿瘤和疾病中,使DNMT3A成为血癌中最常见的突变基因之一;编码染色质重塑蛋白复合物的基因在各种肿瘤中经常发生突变或缺失。因此,DNMT3A和atp依赖的染色质重塑物似乎作为肿瘤抑制因子发挥作用,很可能以一种环境依赖的方式发挥作用。然而,染色质修饰机制的改变如何促进肿瘤的发生仍是一个谜,基于机制的治疗方法有待开发。染色质修饰确保独特的细胞身份。过去的研究已经阐明了染色质修饰的几个原理。一个重要的性质是可逆性。表观基因组状态会根据发育或环境因素(如分化)进行重置。表观遗传变化是由“写”或“擦除”特定染色质修饰的拮抗酶介导的,例如DNA甲基转移酶或去甲基化酶,组蛋白乙酰转移酶(HAT)或去乙酰化酶(HDAC)。其次,表观遗传状态在细胞分裂过程中相对稳定。这种“遗传”部分是由于修饰酶的自我招募来促进自我繁殖。此外,属于同一基因活性或基因抑制类别的不同染色质修饰经常合作形成一个自我强化网络。例如,甲基化的DNA被MeCP2“读取”,它招募hdac使组蛋白去乙酰化(图1)。由于通过拮抗和强化网络的表观遗传串扰,有人会编辑
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation. Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis. The challenge of weight gain in hormone receptor-positive breast cancer. Molecular mechanism of PARP inhibitor resistance. Functional information offers individualized adaptive cancer therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1